ADULT HUMAN LIVER
AnaBios는 Drug Discovery의 모든 단계에 Human Tissue Sample 및 Service를 제공합니다.
ADULT HUMAN LIVER
Physiologically Functional Tissue for Drug Discovery
– AnaBios는 기증에 동의한 성인들로부터 윤리적으로 공급받은 high-quality adult human tissue를 제공합니다.
– Diseased 또는 normal tissue 모두 제공 가능하며 성별, 나이, 인종, BMI를 포함한 인구통계학적 정보를 제공합니다.
| Human Tissue | Diseased | Tissue Types | Uses |
| Liver | Please inquire
cirrhosis, NASH, NAFLD |
Liver samples (bulk and punch), frozen hepatocytes | Genomic sequencing (tissue)
RNAscope, proteomics, IHC |
[Human Liver Tissue Regions]
| Item | Cat # | Item | Cat # | Item | Cat # |
| Coronary Ligament | CAR-104/F | Coronary Ligament – NASH | CAR-104/F | Coronary Ligament – NAFLD | CAR-104/F |
| Dextrose Cells | CAR-108/F | Dextrose Cells – NASH | CAR-108/F | Dextrose Cells – NAFLD | CAR-108/F |
| Gall Bladder | CAR-109/F | Gall Bladder – NASH | CAR-106/F | Gall Bladder – NAFLD | CAR-106/F |
| Left Lobe | CAR-101/F | Left Lobe – NASH | CAR-101/F | Left Lobe – NAFLD | CAR-101/F |
| Portal Vein | CAR-107/F | Portal Vein – NASH | CAR-107/F | Portal Vein – NAFLD | CAR-107/F |
| Right Lobe | CAR-103/F | Right Lobe – NASH | CAR-103/F | Right Lobe – NAFLD | CAR-103/F |
| α-Lipoic Acid Cells | CAR-109/F | α-Lipoic Acid Cells – NASH | CAR-109/F | α-Lipoic Acid Cells – NAFLD | CAR-109/F |
| α-Lipoic Acid + Dextrose | CAR-110/F | α-Lipoic Acid + Dextrose – NASH | CAR-110/F | α-Lipoic Acid + Dextrose – NAFLD | CAR-110/F |
ADULT HUMAN HEPATOCYTES
Primary Human Hepatocytes (PHHGs) Application :
- Drug screening
- Clearance study
- Regulatory induction
- Long-term metabolic stability
- Toxicity
- Transporter studies
- Co-culturing
- Genomics
[Primary Human Hepatocytes (PHHGs) Tissue Regions]
| Item | Cat # |
| Cryo suspension Hepatocytes | HEP-001 |
| Cryo plateable Hepatocytes | HEP-002 |
| Plating Medium | HEP-003 |
| Maintenance Medium | HEP-004 |
Major Cell Types :
- Stellate
- Kupffer
- Liver Sinusoidal Endothelial
- Hepatocytes.
QUALITY CONTROL TESTING
PHH lot based on yield, viability, morphology and plating efficiency.
Each lot is guaranteed to contain a minimum of 3-6 million cells per vial.
* All lot-specific information will be reported on the Certificate of Analysis (CoA)
| Each lot is evaluated for : | Donor information : |
| Post-thaw viability ≥ 75% | death, age, gender, race, BMI, diabetic status, smoking history, alcohol use, drug history & co-morbidities |
| Confluency > 70% on Day 5 | |
| CYP1A2, CYP2B6 and CYP3A4 induction | |
| Metabolic activity of CYP450: 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A, GEN, SULT, UGT, AO | |
| Serology results (via PCR detection) : | Culture results : |
| HBV, HCV, HIV-1, HIV-2, CMV, EBV, SARS-CoV-2 | mycoplasma, fungi, yeast, Gram + and Gram -. |
제품 & 서비스 문의